An observational study in Type 2 Diabetes Mellitus, sponsored by University of Erlangen-Nürnberg Medical School. Completed at 1 site in Germany. Open to participants aged 30 Years to 80 Years. Per ClinicalTrials.gov, last updated 2015-03-25.
Sponsored by University of Erlangen-Nürnberg Medical School · Observational
Basal nitric oxide (NO) activity plays a pivotal role in the regulation of glomerular hemodynamics, and in animal experiments its alteration has been associated with morphological changes characteristic of diabetic nephropathy. The investigators aimed to assess in a prospective study: 1. basal NO activity of renal vasculature and 2. renal hemodynamics to examine whether impairment of basal NO activity of the renal vasculature is related to development and progression of diabetic nephropathy and other cardiovascular endpoints.
10,925 studies on the registry are indexed under Diabetes Mellitus; 1,319 are open to participants now.
This study's planned enrollment of 69 is below the median of 233 across 2,220 observational studies indexed under Diabetes Mellitus.
Browse Diabetes Mellitus studies →University of Erlangen-Nürnberg Medical School is the lead sponsor of 267 studies on the registry; 51 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Subjects with type 2 diabetes mellitus and normo or microalbuminuria
Exclusion Criteria:
Subjects with type 2 diabetes mellitus, eGFR \> 80, hypertension, no overt proteinuria
Drug: Telmisartan 80 mg/d
Subjects with type 2 diabetes mellitus, eGFR \> 80, hypertension, no overt proteinuria
Drug: Ramipril 10 mg/d
Change in eGFR after 1 year
This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Erlangen-Nürnberg Medical School